相关实验视频

Updated: Jan 13, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

一线和二线治疗Zuberitamab在Idiopathic膜性脏病:一个单中心的回顾性研究

Linna Wang¹, Miaomiao Yang¹, Lei Yan¹

¹Department of Nephrology, Henan Provincial People's Hospital, Zhengzhou, People's Republic of China.

Kidney medicine

|January 9, 2026

概括

祖贝里塔马布在治疗异形膜性病症 (IMN) 中表现有前途,达到高缓解率并改善功能. 这种抗CD20疗法即使在对rituximab耐药的患者中也是有效的.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

异形膜性病 (IMN) 是综合征的主要原因之一.
利图西马布是一种常见的治疗方法,但有些患者会产生耐药性或不耐受性.
抗CD20单克隆抗体Zuberitamab是一个潜在的替代疗法.

研究的目的:

评估zuberitamab在患有脂酶A2受体 (PLA2R) 相关IMN的患者中的有效性和安全性.
评估对祖伯利他马布治疗的临床和免疫反应.
为IMN患者,包括对rituximab耐药的患者,探索zuberitamab作为治疗选择.

主要方法:

一项追溯观察队列研究,涉及60名患有PLA2R相关IMN的患者.
患者接受佐伯利他马布作为一线或二线治疗.
结果包括蛋白尿缓解,血清白蛋白,肌素,估计的球过率,CD19+ B细胞和抗PLA2R抗体标位.

主要成果:

在3个月后,80%的患者实现了完全或部分缓解.
在6个月后,血清白蛋白显著改善,蛋白尿和肌素减少.
在一线和二线治疗组中都观察到抗PLA2R抗体正常化的高率,没有报告严重不良事件.

结论:

祖伯利他马布在IMN患者中表现出良好的临床和免疫反应.
这种疗法在以前用Rituximab治疗的患者中显示出疗效.
这些发现表明zuberitamab是IMN的潜在治疗选择,值得在前性研究中进一步调查.

关键词:

B细胞的枯竭导致B细胞的枯竭.针对CD20的向疗法双病性膜性神经病变 - - 双病性膜性神经病变淋巴细胞疾病是什么?脏性范围蛋白尿症脏范围蛋白尿症脂酶A2受体抗体的抗体在这里,我们可以看到Zuberitamab.

更多相关视频

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Acute Pyelonephritis II: Diagnostic Studies and Management

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...